Analysts Set Hikma Pharmaceuticals PLC (LON:HIK) Price Target at GBX 1,687

Shares of Hikma Pharmaceuticals PLC (LON:HIK) have received a consensus rating of “Buy” from the six research firms that are presently covering the stock, MarketBeat.com reports. Six research analysts have rated the stock with a buy rating. The average 1-year target price among analysts that have issued a report on the stock in the last year is GBX 1,687.

Several research firms recently weighed in on HIK. Berenberg Bank restated a “buy” rating and issued a GBX 1,800 target price on shares of Hikma Pharmaceuticals in a report on Tuesday, April 28th. Jefferies Financial Group increased their price target on Hikma Pharmaceuticals from GBX 1,850 to GBX 1,870 and gave the company a “buy” rating in a report on Tuesday, May 5th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and issued a GBX 195 price target on shares of Hikma Pharmaceuticals in a research report on Monday, June 22nd. Finally, Citigroup restated a “buy” rating on shares of Hikma Pharmaceuticals in a research note on Thursday.

Hikma Pharmaceuticals Trading Up 0.6%

Hikma Pharmaceuticals stock opened at GBX 1,561 on Thursday. The company has a debt-to-equity ratio of 61.84, a current ratio of 1.82 and a quick ratio of 1.27. The company has a market capitalization of £3.28 billion, a price-to-earnings ratio of 8.62, a PEG ratio of 2.38 and a beta of 0.65. Hikma Pharmaceuticals has a one year low of GBX 1,187 and a one year high of GBX 2,052. The company’s fifty day moving average price is GBX 1,492.24 and its two-hundred day moving average price is GBX 1,449.18.

Hikma Pharmaceuticals Company Profile

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 820+ (as of Feb 2026) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.